Loading
JP
La Jolla Pharmaceutical Co Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by RAMSAY DAVID A, was filed 06 Dec 2021.
La Jolla Pharmaceutical Co: what insiders have been doing
La Jolla Pharmaceutical Co belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). The past year has been quiet: not a single insider filing for La Jolla Pharmaceutical Co. The previous disclosure was published on 24 August 2022.
Looking back to 2016, when coverage begins, insiders filed 163 purchases and 15 sales.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
420
Thresholds
n/a
Buy Volume
€84M
163 ops. · all time
Sell Volume
€12M
15 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2020FY ended December 2020 · cache
Income statement
RevenueUS$28.8M
Net incomeUS$16.9M58.8% margin
Last declaration on 24 August 2022
Declarations420 total
9,607,934 shares@ US$6.2399.8% of flowCommon StockSEC:0000899243-22-029649:1
9,607,934 shares@ US$6.2398.3% of flowCommon StockSEC:0001209191-22-047314:0
10,186 shares@ US$6.2375.0% of flowCommon StockSEC:0000899243-22-029649:0
11,969 shares@ US$6.2366.7% of flowCommon StockSEC:0000899243-22-029657:0
500 shares@ US$6.23100.0% of flowCommon StockSEC:0000899243-22-029651:0
100,000 shares@ US$6.2393.8% of flowCommon StockSEC:0000899243-22-029662:0
12,000 shares@ US$6.2361.9% of flowCommon StockSEC:0000899243-22-029650:0
12,000 shares@ US$3.9338.1% of flowCommon StockSEC:0001209191-22-041988:0
236 shares@ US$2.71150.7% of flowCommon StockSEC:0001209191-22-040873:0
236 shares@ US$2.720.7% of flowCommon StockSEC:0001209191-22-037956:0
189 shares@ US$3.40850.7% of flowCommon StockSEC:0001209191-22-033597:0
188 shares@ US$3.40850.7% of flowCommon StockSEC:0001209191-22-029751:0
185 shares@ US$3.4680.7% of flowCommon StockSEC:0001209191-22-026783:0
296 shares@ US$3.71450.9% of flowCommon StockSEC:0001209191-22-024635:0
173 shares@ US$3.71450.7% of flowCommon StockSEC:0001209191-22-024634:0
177 shares@ US$3.62950.7% of flowCommon StockSEC:0001209191-22-022587:0
334 shares@ US$3.62951.0% of flowCommon StockSEC:0001209191-22-022588:0
190 shares@ US$3.3660.7% of flowCommon StockSEC:0001209191-22-019899:0
361 shares@ US$3.3661.0% of flowCommon StockSEC:0001209191-22-019905:0
350 shares@ US$3.47651.0% of flowCommon StockSEC:0001209191-22-014884:0
185 shares@ US$3.47650.7% of flowCommon StockSEC:0001209191-22-014875:0
320 shares@ US$3.7911.0% of flowCommon StockSEC:0001209191-22-010874:0
169 shares@ US$3.7910.7% of flowCommon StockSEC:0001209191-22-010852:0
4,170 shares@ US$3.935513.1% of flowCommon StockSEC:0001209191-22-006562:0
1,675 shares@ US$3.93556.9% of flowCommon StockSEC:0001209191-22-006559:0
25 of 420 declarations
About La Jolla Pharmaceutical Co
La Jolla Pharmaceutical Company (ticker: LJPC) was a U.S. biopharmaceutical company focused on the development and commercialization of therapies for serious, often hospital-based diseases. Historically, LJPC was listed on the NASDAQ market in the United States, but in August 2022 the company was acquired by Innoviva. Following the transaction, La Jolla became a wholly owned subsidiary of Innoviva and its common stock was delisted from NASDAQ. For equity investors, this is a critical point: LJPC is no longer an independent publicly traded stock, although its legacy assets and historical disclosures remain relevant in SEC filings and in the broader Innoviva portfolio. ([sec.gov](https://www.sec.gov/Archives/edgar/data/920465/000119312522226088/d382789dex99a5b.htm?utm_source=openai))
The company was founded in California and was headquartered in La Jolla, California, reflecting its origins as a U.S.-based specialty pharma developer. Its business model centered on identifying unmet medical needs and translating them into products with clinical utility in high-acuity settings. The historical commercial platform was anchored by GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA® (eravacycline), used for complicated intra-abdominal infections. In addition to these marketed products, La Jolla pursued development programs in infectious disease, illustrating a pipeline strategy oriented toward medically complex, high-need niches rather than broad primary-care indications. ([sec.gov](https://www.sec.gov/Archives/edgar/data/920465/000092046518000007/ljpc-201710xk.htm?utm_source=openai))
Read moreShow less
From a competitive standpoint, La Jolla was a specialty player rather than a diversified large-cap pharmaceutical company. Its addressable markets were highly competitive, with alternatives offered by larger hospital-focused and anti-infective franchises. The company’s differentiation depended on clinical relevance, targeted use in acute-care settings, and the ability to commercialize products in areas where physicians face meaningful therapeutic gaps. Geographically, the business was primarily U.S.-oriented, with product distribution in the United States handled through distributors and select wholesalers serving hospitals as end customers. That U.S. footprint and hospital-channel focus were central to the company’s operating model and its revenue generation before the acquisition. ([sec.gov](https://www.sec.gov/Archives/edgar/data/920465/000092046519000044/ljpc-201810xk.htm?utm_source=openai))
The most important recent corporate event was the 2022 acquisition by Innoviva, which effectively ended LJPC’s life as an independent listed issuer. For analysts and investors, that means any current reference to La Jolla Pharmaceutical should be read in a historical or subsidiary context, not as a standalone NASDAQ-listed name. In practical terms, the company’s legacy now sits inside Innoviva’s healthcare asset base, while the standalone LJPC ticker no longer represents an active publicly traded equity opportunity in the U.S. market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/920465/000119312522226088/d382789dex99a5b.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
